The Role of Cyclic-AMP Binding Protein (CREB) in Leukemia Cell Proliferation and Acute Leukemias

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2004 Apr 23

PMID 15101710

Citations 18

Authors

Deepa B Shankar

Kathleen M Sakamoto

Affiliations

Soon will be listed here.

Abstract

Leukemia is a result of accumulating genetic alterations. The collaboration of mutations that offer survival and proliferative signals, together with mutations that result in lack of differentiation, is thought to cause a leukemic phenotype. The cyclic-AMP Response Element Binding Protein (CREB) is a transcription factor that is known to be a downstream component of the GM-CSF and IL-3 signaling pathways. We previously showed that CREB is overexpressed in blast cells from patients with acute leukemias. In this paper, we review the role of CREB in hematopoiesis, cell proliferation and acute leukemias.

Citing Articles

CREB1 contributes colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways.

Li B, Zheng L, Ye J, Zhang C, Zhou J, Huang Q Sci China Life Sci. 2022; 65(8):1481-1497.

PMID: 35696016 DOI: 10.1007/s11427-022-2108-x.

Increased phosphorylated CREB1 protein correlates with poor prognosis in clear cell renal cell carcinoma.

Zhang Z, Guan B, Li Y, He Q, Li X, Zhou L Transl Androl Urol. 2021; 10(8):3348-3357.

PMID: 34532259 PMC: 8421817. DOI: 10.21037/tau-21-371.

Antileukemic Activity and Molecular Docking Study of a Polyphenolic Extract from Coriander Seeds.

Mechchate H, de Oliveira R, Es-Safi I, Mourao E, Bouhrim M, Kyrylchuk A Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451867 PMC: 8400422. DOI: 10.3390/ph14080770.

Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer.

Mantamadiotis T Cancers (Basel). 2017; 9(6).

PMID: 28556811 PMC: 5483879. DOI: 10.3390/cancers9060060.

MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.

Sun S, Wang X, Xu X, Di H, Du J, Xu B Oncotarget. 2016; 8(3):5057-5068.

PMID: 27926502 PMC: 5354892. DOI: 10.18632/oncotarget.13789.